Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1qin the CSF.
CLICK HERE FOR FULL STORY
